Health Canada Approves LEQEMBI for Early Alzheimer's Treatment
Eisai and Biogen Canada Inc. announced that Health Canada has authorized LEQEMBI (lecanemab) for treating early Alzheimer's disease.
In Canada, LEQEMBI is indicated for adult patients with mild cognitive impairment or mild dementia due to Alzheimer's disease, specifically those who are apolipoprotein E ε4 (ApoE ε4) non-carriers or heterozygotes with confirmed amyloid pathology.
For more information, contact 877-269-7890 from 8 AM - 10 PM ET.
No direct quote available in the provided text.
Author's summary: LEQEMBI authorized in Canada for early Alzheimer's treatment.
More News
- Canada’s Lululemon Partners With National Football League
- Community pharmacies and BioPharma: Advancing whole-patient care together
- Which Non-League sides will take part in the Isuzu FA Trophy Second Round Proper? - The Non-League Football Paper
- Tapering Methotrexate Is Feasible in Stable RA With Careful Monitoring
- Sony PlayStation 5 Power Saver mode slashes power by half | Club386
- Lupus Foundation of America Honors Outstanding Achievements in Lupus Research
- Managing Benign Prostatic Hyperplasia: Your BPH Treatment Options
- Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
- Banks’ stampede for deposits to intensify
- The Turkish glees, language barrier